Daiichi Sankyo -Initiation of Phase 3 Trial of CHS-0214...
The primary endpoint is ACR 20*2 at 24 weeks. as bio-kozokuhin or 'follow-on biologics') are biologic medical products that are similar to already approved biotechnology applied pharmaceuticals but are developed by a different manufacturer.
Thu Jul 31, 2014
Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2...
Key results include: Total revenues increased 11 percent to , with 8 percent product sales growth driven by strong performance across the portfolio, particularly Enbrel , Kyprolis , Prolia and XGEVA .
Wed Jul 30, 2014
New Crohn's Disease Findings from University of Cambridge Discussed...
This contrasts with other immune-related diseases considered mechanistically and genetically closely related, such as psoriasis and rheumatoid arthritis, where approved biologics target a variety of independent biological mechanisms."
Tue Jul 29, 2014
The Washington Post
Amgen Profit Tops Estimates as 2,400 Jobs Will Be Cut
Amgen Inc., the world's biggest biotechnology company by sales, reported second-quarter earnings that beat analysts' estimates and raised its profit estimate for the year.
Amgen to close Washington state operations; 700 jobs on the line
Amgen is cutting 12-15 percent of its workforce over the next year, and will be closing its facilities in Seattle and Bothell, which currently employ 710 workers.
Smoking linked to negative disease progression from smoking
Psoriatic arthritis, is an inflammatory form of arthritis associated with psoriasis and includes many manifestations such as skin psoriasis, nail lesions, dactylitis, and enthesitis.
Mon Jul 28, 2014
Pfizer Dips On BMO Downgrade
So concludes BMO Capital Markets today in a downgrade report, which sent shares of Pfizer down nearly 1% to $29.86.
Biologic treatments for RA carry similar infection risk
The risk of hospitalized bacterial infections in older rheumatoid arthritis patients is similar for rituximab or abatacept compared to etanercept, although it is higher for infliximab, according to a study published in the July issue of Arthritis Care & Research .
Thu Jul 24, 2014
Infliximab efficacy in rheumatoid arthritis after an inadequate...
Infliximab efficacy in rheumatoid arthritis after an inadequate response to etanercept or adalimumab: results of a target-driven active switch study.
Wed Jul 23, 2014
Mon Jul 21, 2014
The Otago Daily Times
Much interest in stroke treatment
A Dunedin man believed to be the first New Zealander to undergo innovative stroke therapy in the United States may have become a trailblazer.